Trial Profile
Assessment of Safety and Immunogenicity of Intradermal Electroporation of tetwtCEA DNA in Patients With Colorectal Cancer.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 22 Aug 2022
Price :
$35
*
At a glance
- Drugs Carcinoembryonic antigen DNA vaccine (Primary) ; Cyclophosphamide; Granulocyte macrophage colony stimulating factor; Granulocyte macrophage colony stimulating factor
- Indications Colorectal cancer
- Focus Pharmacodynamics
- Acronyms El-porCEA
- 18 Aug 2022 Status changed from active, no longer recruiting to completed.
- 27 Feb 2012 Planned End Date changed from 1 Jun 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 27 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.